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Abstract. Glioblastomas are the most malignant gliomas with median survival times of only 15 months despite modern therapies.
All standard treatments are palliative. Pathogenetic factors are diverse, hence, stratified treatment plans are warranted considering
the molecular heterogeneity among these tumors. However, most patients are treated with “one fits all” standard therapies, many
of them with minor response and major toxicities. The integration of clinical and molecular information, now becoming available
using new tools such as gene arrays, proteomics, and molecular imaging, will take us to an era where more targeted and effective
treatments may be implemented.
A first step towards the design of such therapies is the identification of relevant molecular mechanisms driving the aggressive
biological behavior of glioblastoma. The accumulation of diverse aberrations in regulatory processes enables tumor cells to
bypass the effects of most classical therapies available. Molecular alterations underlying such mechanisms comprise aberrations
on the genetic level, such as point mutations of distinct genes, or amplifications and deletions, while others result from epigenetic
modifications such as aberrant methylation of CpG islands in the regulatory sequence of genes. Epigenetic silencing of the
MGMT gene encoding a DNA repair enzyme was recently found to be of predictive value in a randomized clinical trial for newly
diagnosed glioblastoma testing the addition of the alkylating agent temozolomide to standard radiotherapy. Determination of
the methylation status of the MGMT promoter may become the first molecular diagnostic tool to identify patients most likely to
respond that will allow individually tailored therapy in glioblastoma.
To date, the test for the MGMT-methylation status is the only tool available that may direct the choice for alkylating agents in
glioblastoma patients, but many others may hopefully become part of an arsenal to stratify patients to respective targeted therapies
within the next years.
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1. Introduction
Despite the use of combined treatment regimens in-
cluding resection, radiotherapy, and chemotherapy, the
prognosis for patients with glioblastoma, the most ma-
lignant form of glioma (WHO grade IV), remains un-
favorable [5,25,40]. At the time of diagnosis, median
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survival is around 15 months [44], and at tumor recur-
rence, life expectancy is a few months only [2].
Consequently, individually tailored therapies for pa-
tients with high-grade gliomas are an important issue
in modern patient management. Efforts are numer-
ous to find factors identifying patients likely to ben-
efit from the treatments considered. The first step to
this is to identification of biologically and clinically
relevant molecular changes. This has become eas-
ier within the last years by new technologies allow-
ing high-throughput analyses in the fields of genomics,
epigenomics, and proteomics. However, the true rel-
evance of this descriptive information in the clinical
setting depends on its prognostic and predictive value,
and the possibility of targeting the respective molecular
mechanisms specifically, will translate into efficacious
treatments.
In recent years, research has focused on so called
epigenetic alterations in tumors. These are heritable
changes in gene function that occur without a change
in the sequence of nuclear DNA. Epigenetic regula-
tion of genes plays a major role in development [21].
There has been rapid progress in understanding epi-
genetic mechanisms in cancer, which include aberrant
DNA methylation at CpG islands, as well as changes
in chromatin structure mediated by mechanisms such
as histone acetylation [18]. Hypermethylation of CpG
islands in the promoter of genes leads to loss of expres-
sion, while loss of methylation in normally silenced
genes may cause inappropriate expression (e.g. IGF2
gene). Both may have tumor promoting effects. In the
course of tumor development, epigenetic silencing is
known as an early and important mechanism for inacti-
vation of tumor suppressor genes [9]. Pathways dereg-
ulated or inactivated by promoter hypermethylation of
key genes comprise the cell cycle, apoptosis, DNA-
repair, growth factor response, and invasion/cell struc-
ture [18]. Similar to other tumor associated molecular
changes, epigenetic silencing of cancer relevant genes
display typical, tumor type dependent frequencies of
such alterations [6].
Efforts to develop drugs to reactivate hypermethy-
lated tumor suppressor genes or to deactivate tumor
promoting genes as therapy of cancer are ongoing [4,
6,18].
2. The role of MGMT in resistance to alkylating
chemotherapy
Epigenetic silencing of the O-6-methylguanine-DNA
methyltransferase (MGMT) gene by promoter methy-
lation has been recognized as an important factor to
predict outcome in glioblastoma patients treated with
alkylating agents such as temozolomide (TMZ) and car-
mustine (BCNU) [8,16]. The MGMT gene is located
on chromosome 10q26 and codes for an excision repair
enzyme removing alkyl-groups from the O6-position of
guanine, one of the targets of alkylating agents (Fig. 1).
In this process the alkyl group is transferred to the ac-
tive site of the MGMT protein that thereby becomes
irreversibly inactivated and subsequently degraded, re-
quiring resynthesis. Although O6-methyl guanine ac-
counts for less than 10% of the lesions induced by alky-
lating agents, it plays a major role as a trigger for cyto-
toxicity and apoptosis [33]. If left unrepaired, e.g. due
to epigenetic silencing of the MGMT gene or depletion
of the MGMT protein by saturation of the process, O6-
methyl guanine persists in the DNA. The current hy-
pothesis proposes that O6-methyl guanine forms mis-
pairs with thymine after replication that are recognized
by the mismatch repair (MMR) system. However, since
MMR is directed to the newly synthesized strand, while
the O6-methyl guanine resides in the template strand,
the lesion is not repaired, but engages MMR in what
is called futile repair cycles that eventually lead to cell
death [23]. Thus, suggesting that in addition to an in-
activated MGMT gene, MMR-proficiency is an impor-
tant factor for response. In line with this mechanism,
it has been reported that cells deficient for MMR are
100 times more resistant to alkylating drugs even in
absence of MGMT [41].
Taken together, high endogenous MGMT activity in
tumors reverses in part the impact of alkylating drugs
widely used in oncology [13]. MGMT therefore plays
a key role in mechanisms conferring resistance to treat-
ments with alkylating agents, in particular to Temo-
zolomide [11,20,39].
3. Epigenetic silencing of MGMT predicts benefit
from Temozolomide treatment
The MGMT methylation status was first established
as an independent prognostic factor in a phase II trial
treating newly diagnosed glioblastoma patients with ra-
diotherapy and concomitant and adjuvant Temozolo-
mide [16,42] and previously for patients treated with
nitrosourea chemotherapy [8,20]. The subsequent ran-
domized phase III trial enrolling 573 patients conducted
by the European Organisation for Research and Treat-
ment of Cancer (EORTC) and the National Cancer In-
stitute of Canada (NCIC) Clinical Trials Group [44]
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Fig. 1. MGMT mediated repair of O6-methylguanine. The MGMT restores guanine by removing the alkyl-adduct (here represented by a methyl
group) from the O6-position of guanine. The transfer of the alkyl-group to the active site of the enzyme inactivates the protein irreversibly and
the protein is subjected to degradation [13].
provided the unique opportunity to test the MGMT
methylation status as a predictive factor for response
to temozolomide treatment. The trial has shown that
the addition of concomitant and adjuvant TMZ to ra-
diotherapy (RT) improved the 2-year survival rate from
10% in the RT group to 26% for TMZ/RT, setting a
new standard of care for glioblastoma patients [42].
In the subgroup of patients with a methylated MGMT
promoter the drug proved to be even more active. At
2 years, 46% of the patients treated with TMZ/RT and
whose tumors were MGMT methylated survived, com-
pared to only 14% for the patients with unmethylated
tumors. Promoter methylation status was identified by
Methylation Specific PCR (MSP) in the DNA isolated
from the tumor tissues of over 200 of the patients. The
benefit of the addition of TMZ chemotherapy was ba-
sically confined to patients whose tumors had a methy-
lated MGMT promoter [17] (Table 1, Fig. 2).
A confounding factor in the study was that 60%
of the patients randomized to radiation alone received
TMZ at progression. When analyzing progression-free
survival, the notion that benefit from TMZ is confined
to patients with a methylated MGMT is confirmed. A
median progression free survival of 10.3 months was
observed in patients treated with TMZ and radiation,
as opposed to 5.3 months in the radiation only group.
The latter is similar to patients with an ummethylated
MGMT either treated with radiation alone or the com-
bined treatment [17] (Table 1). These data and mech-
anistic considerations detailed above strongly suggest
that the MGMT promoter status is a predictive factor for
benefit from Temozolomide treatment. It is of note that
the MGMT methylation status did not correlate with
age and that older patients benefited similarly from the
treatment depending mainly on their MGMT status.
4. Other resistance factors
However, additional tumor resistance mechanisms to
TMZ-chemoradiation exist that need to be identified in
order to propose additional treatments to those patients
who don’t respond despite a methylated MGMT status.
Inactivation of the MMR pathway is crucial for me-
diating the cytotoxic effect of alkylating agents in ab-
sence of MGMT. Microsatellite Instability (MSI), a
measure for MMR-deficiency, or epigenetic silencing
of a hMLH1, which codes for a key component of the
MMR-complex, were not detected in glioblastoma of
adult patients [1,6,22,27]. However, both was identi-
fied in few glioblastoma samples of pediatric patients
with familial history of cancer [1,22]. Hence, inactiva-
tion of MMR function is likely not an important fac-
tor for resistance in adult glioblastoma patients. MSI
associated with epigenetic inactivation of hMLH1 are
frequently found in sporadic colon cancer, cancer of the
uterus, and stomach cancer [6]. MSI results from unre-
paired slippage of the DNA polymerase during replica-
tion of nucleotide repeats that normally is recognized
and repaired by MMR.
Recent comprehensive molecular profiling efforts
provided evidence for the existence of molecular sub-
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Table 1
Impact of the methylation status of the MGMT promoter on Temozolomide-treatment
mediated benefit on survival (with permission from Hegi et al., 2005 [17]). The table
shows progression free and overall survival times separated for patients with methylated
and unmethylated MGMT promote, respectively
Randomization Total RT TMZ/RT
Number of patients N = 206 N = 100 N = 106
MGMT methylated N = 92 N = 46 N = 46
Progression Free Survival
Median PFS [95% CI] months 5.9 [5.3;7.7] 10.3 [6.5;14.0]
6 months PFS rate [95% CI] (%) 47.8 [33.4;62.3] 68.9 [55.4;82.4]
Overall Survival
Median survival [95% CI] months 15.3 [13.0;20.9] 21.7 [17.4;30.4]
2-yr survival rate [95% CI] (%) 22.7 [10.3;35.1] 46.0 [31.2;60.8]
MGMT unmethylated N = 114 N = 54 N = 60
Progression Free Survival
Median PFS [95% CI] months 4.4 [3.1;6.0] 5.3 [5.0;7.6]
6 months PFS rate [95% CI] (%) 35 [22.5;47.9] 40.0 [27.6;52.4]
Overall Survival
Median survival [95%CI] months 11.8 [9.7;14.1] 12.7 [11.6;14.4]
2-yr survival rate [95% CI] (%) 1.9 [0.0;5.5] 13.8 [4.8;22.7]
Legend: CI, confidence interval.
Fig. 2. Overall survival of glioblastoma patients randomized in the EORTC/NCIC-trial according to MGMT methylation status [17,44] Ka-
plan-Meier survival estimates indicate that the patient group with a methylated MGMT status and randomized to TMZ/RT do best. The patient
group with methylated MGMT promoter randomized to RT alone had a favorable overall survival, likely reflecting benefit from TMZ treatment
at recurrence (Reproduced with permission. Copyright c© 2005, Massachusetts Medical Society. All rights reserved.).
types of glioblastoma that may differ in their clini-
cal behavior [3,10,14,19,26,31,32,34,36,37]. Several
prognostic factors emerged from these and other retro-
spective studies, however, the insights gained will re-
quire validation in independent data sets and prospec-
tive clinical trials to determine their predictive value for
response to therapeutic interventions.
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5. Implementation of the MGMT test in routine
diagnostics – are we there yet?
Determination of MGMT methylation status by MSP
is an important step towards molecular diagnostics. It
provides the opportunity to identify patients likely to
benefit from TMZ treatment. Ongoing clinical trials
comprising temozolomide as part of the treatment regi-
men need to stratify for the MGMT status when testing
the addition of targeted, small molecule drugs such as
inhibitors of tyrosine kinases or integrins implicated in
tumor growth and angiogenesis. Preselecting patients
by MGMT methylation status will increase patient ho-
mogeneity.
The impact of the MGMT methylation status in
glioblastoma requires validation. A large random-
ized international intergroup trial (RTOG 0525/EORTC
26052-22053) has opened in January 2006. It will treat
the patients according to the new standard of care and
stratify the patients for the MGMT methylation status.
This will allow validation of the previous finding, while
attempting to overcome MGMT based tumor resistance
in the experimental arm by providing a dose dense,
intensified temozolomide schedule in the maintenance
part, expected to deplete MGMT in the tumor tissue
(see outline and treatment schedule in the recent review
by Stupp et al. [43]). The MGMT status will be deter-
mined with a direct real-time fluorescence–based MSP
(Califice, manuscript submitted) that has been adjusted
to and validated with the gel based assay reported pre-
viously [17]. This new assay will allow high through-
put analysis and due to its quantitative nature may al-
low adjustment of the cut-off for methylated versus
non-methylated MGMT at the end of the clinical trial
to improve outcome prediction.
At present, for patients with an unmethylated MGMT
promoter, the addition of TMZ increases the median
survival by less than one month from 11.8 to 12.7 (lo-
grank test P = 0.06) (Table 1, Fig. 2). These pa-
tients may profit from other therapies based on differ-
ent mechanisms of action, and may be spared the toxi-
city of TMZ. However, no other efficacious treatments
are currently available. Nevertheless, patients may be
demanding the test in order to decide for or against
chemotherapy, or to seek participation in a clinical trial
evaluating agents with a different mechanism of action.
Until fully validated, MGMT testing may be further in-
dicated in specific clinical circumstances. In patients
developing toxicity to the treatment or with a deterio-
rating performance status, the knowledge of the MGMT
promoter methylation status may incite continuation or
discontinuation of treatment.
In the future, specific treatments need to be designed
and offered to patients with an unmethylated MGMT.
Beside other modes of action, strategies comprise the
use of specific inhibitors of MGMT, such as the non-
toxic substrate O6-benzyl guanine depleting cells of
MGMT, expected to render tumors more sensitive to
alkylating agent chemotherapy [35]. Other substances
modulating MGMT expression may also improve re-
sponse to alkylating agents [30,45].
6. Evaluation of the MGMT status
The presented correlation between MGMT and pre-
diction of benefit from Temozolomide treatment is
based on the determination of the methylation status
of the MGMT gene promoter in the tumor tissue [17].
Attempts are made to evaluate MGMT at the protein
level, or testing MGMT activity in the tumor tissue.
For diagnostic purposes the advantage of methylation
specific PCR lies in the fact that the methylated MGMT
allele is contributed solely by the tumor tissue, and non-
tumoral tissue contamination does not interfere with
the result [38]. Furthermore, MGMT may be induced
in tumor cells not only in response to DNA damage
introduced by alkylating agents and radiotherapy but
also by corticosteroids [12,15]. Therefore, since aber-
rant methylation of CpGs is an inheritable change of
DNA in the clonal expansion of the tumor [46], the
methylation status of the MGMT promoter may be a
more reliable marker predicting inducibility of MGMT
once the cancer treatment is initiated than MGMT lev-
els determined at the time of diagnosis [12,24]. More-
over, MSP yields a clear read-out. However, the test
requires good quality paraffin embedded tissue that is
not overfixed. In contrast, immunohistochemistry or
enzymatic methods may be obscured by the presence of
non-tumoral cells and tumor infiltrating lymphocytes
in the biopsy that may express MGMT, and retain an
unmethylated MGMT promoter status. In our experi-
ence, evaluation of immunohistochemistry for MGMT
is prone to strong interobserver discrepancies that are
even more pronounced when comparing readings from
different centers (unpublished results).
7. Extrapolation to other tumor types
In clinical trials evaluating TMZ for lower grade
glioma and other tumor types such as melanoma and
102 P. Hau et al. / MGMT methylation status: The advent of stratified therapy in glioblastoma?
NSCLC, the relationship of the MGMT methylation
status and response to alkylating chemotherapy has
not yet been established, while it had been associated
with better prognosis in lymphoma patients treated with
alkylating agents [7]. It will be of particular inter-
est to evaluate the relevance of MGMT methylation in
oligodendroglioma. In oligodendroglioma with LOH
1p/19q, a subtype considered particularly sensititve to
chemotherapy, MGMT promoter methylation was de-
tected at a frequency of almost 90% [29].
8. Conclusions
Determination of the MGMT methylation status by
MSP is an important step towards molecular diagnos-
tics. It provides the opportunity to identify patients
likely to benefit from TMZ treatment. These exciting
results have moved the field and will incite new re-
search aiming at identifying tumor specific prognos-
tic and predictive molecular characteristics, a prereq-
uisite for individually tailored therapy. For new tri-
als the collection of tumor tissue, best a paraffin block
and snap frozen tissue, and other relevant biological
material should be mandatory. Subsequent molecular
analysis will allow insights into molecular mechanisms
underlying success or failure of the treatment strategy.
In either case this information will be invaluable for
further improvements that are definitely needed.
In the future, tumors may undergo molecular profil-
ing for the identification of the individually altered key
pathways that point to the most beneficial therapeutic
modality for the respective patient. Response to ther-
apy may be monitored using molecular imaging probes
and/or serum biomarkers [28].
References
[1] M. Alonso, R. Hamelin, M. Kim, K. Porwancher, T. Sung,
P. Parhar, D.C. Miller and E.W. Newcomb, Microsatellite in-
stability occurs in distinct subtypes of pediatric but not adult
central nervous system tumors, Cancer Res 61 (2001), 2124–
2128.
[2] A.A. Brandes and M.V. Fiorentino, The role of chemotherapy
in recurrent malignant gliomas: an overview, Cancer Invest
14 (1996), 551–559.
[3] M. Bredel, C. Bredel, D. Juric, G.E. Duran, R.X. Yu, G.R.
Harsh, H. Vogel, L.D. Recht, A.C. Scheck and B.I. Sikic,
Tumor necrosis factor-alpha-induced protein 3 as a putative
regulator of nuclear factor-kappaB-mediated resistance to O6-
alkylating agents in human glioblastomas, J Clin Oncol 24
(2006), 274–287. Epub 2005 Dec 19.
[4] J.F. Costello, M.C. Fruhwald, D.J. Smiraglia, L.J. Rush, G.P.
Robertson, X. Gao, F.A. Wright, J.D. Feramisco, P. Peltomaki,
J.C. Lang, D.E. Schuller, L. Yu, C.D. Bloomfield, M.A.
Caligiuri, A. Yates, R. Nishikawa, H. Su Huang, N.J. Petrelli,
X. Zhang, M.S. O’Dorisio, W.A. Held, W.K. Cavenee and C.
Plass, Aberrant CpG-island methylation has non-random and
tumour-type-specific patterns, Nat Genet 24 (2000), 132–138.
[5] F.G. Davis, S. Freels, J. Grutsch, S. Barlas and S. Brem, Sur-
vival rates in patients with primary malignant brain tumors
stratified by patient age and tumor histological type: an anal-
ysis based on Surveillance, Epidemiology, and End Results
(SEER) data, 1973–1991, J Neurosurg 88 (1998), 1–10.
[6] M. Esteller, P.G. Corn, S.B. Baylin and J.G. Herman, A gene
hypermethylation profile of human cancer, Cancer Res 61
(2001), 3225–3229.
[7] M. Esteller, G. Gaidano, S.N. Goodman, V. Zagonel, D.
Capello, B. Botto, D. Rossi, A. Gloghini, U. Vitolo, A. Car-
bone, S.B. Baylin and J.G. Herman, Hypermethylation of the
DNA repair gene O(6)-methylguanine DNA methyltransferase
and survival of patients with diffuse large B-cell lymphoma, J
Natl Cancer Inst 94 (2002), 26–32.
[8] M. Esteller, J. Garcia-Foncillas, E. Andion, S.N. Goodman,
O.F. Hidalgo, V. Vanaclocha, S.B. Baylin and J.G. Herman,
Inactivation of the DNA-repair gene MGMT and the clinical
response of gliomas to alkylating agents, N Engl J Med 343
(2000), 1350–1354.
[9] M.F. Fraga, M. Herranz, J. Espada, E. Ballestar, M.F. Paz,
S. Ropero, E. Erkek, O. Bozdogan, H. Peinado, A. Niveleau,
J.H. Mao, A. Balmain, A. Cano and M. Esteller, A mouse skin
multistage carcinogenesis model reflects the aberrant DNA
methylation patterns of human tumors, Cancer Res 64 (2004),
5527–5534.
[10] W.A. Freije, F.E. Castro-Vargas, Z. Fang, S. Horvath, T.
Cloughesy, L.M. Liau, P.S. Mischel and S.F. Nelson, Gene ex-
pression profiling of gliomas strongly predicts survival, Can-
cer Res 64 (2004), 6503–6510.
[11] H.S. Friedman, R.E. McLendon, T. Kerby, M. Dugan, S.H.
Bigner, A.J. Henry, D.M. Ashley, J. Krischer, S. Lovell, K.
Rasheed, F. Marchev, A.J. Seman, I. Cokgor, J. Rich, E.
Stewart, O.M. Colvin, J.M. Provenzale, D.D. Bigner, M.M.
Haglund, A.H. Friedman and P.L. Modrich, DNA mismatch re-
pair and O6-alkylguanine-DNA alkyltransferase analysis and
response to Temodal in newly diagnosed malignant glioma, J
Clin Oncol 16 (1998), 3851–3857.
[12] G. Fritz, K. Tano, S. Mitra and B. Kaina, Inducibility of the
DNA repair gene encoding O6-methylguanine-DNA methyl-
transferase in mammalian cells by DNA-damaging treatments,
Mol Cell Biol 11 (1991), 4660–4668.
[13] S.L. Gerson, MGMT: its role in cancer aetiology and cancer
therapeutics, Nat Rev Cancer 4 (2004), 296–307.
[14] S. Godard, G. Getz, M. Delorenzi, P. Farmer, H. Kobayashi,
I. Desbaillets, M. Nozaki, A.C. Diserens, M.F. Hamou, P.Y.
Dietrich, L. Regli, R.C. Janzer, P. Bucher, R. Stupp, N. de
Tribolet, E. Domany and M.E. Hegi, Classification of human
astrocytic gliomas on the basis of gene expression: a correlated
group of genes with angiogenic activity emerges as a strong
predictor of subtypes, Cancer Res 63 (2003), 6613–6625.
[15] T. Grombacher, S. Mitra and B. Kaina, Induction of the alkyl-
transferase (MGMT) gene by DNA damaging agents and
the glucocorticoid dexamethasone and comparison with the
response of base excision repair genes, Carcinogenesis 17
(1996), 2329–2336.
[16] M.E. Hegi, A.-C. Diserens, S. Godard, P.Y. Dietrich, L.
Regli, S. Ostermann, P. Otten, G. Van Melle, N. de Tribolet
P. Hau et al. / MGMT methylation status: The advent of stratified therapy in glioblastoma? 103
and R. Stupp, Clinical trial substantiates the predictive value
of MGMT-methylation in glioblastoma patients treated with
temozolomide, Clin Cancer Res 10 (2004), 1871–1874.
[17] M.E. Hegi, A.C. Diserens, T. Gorlia, M.F. Hamou, N. de
Tribolet, M. Weller, J.M. Kros, J.A. Hainfellner, W.P. Mason,
L. Mariani, J.E.C. Bromberg, P. Hau, R.O. Mirimanoff, G.
Cairncross, R. Janzer and R. Stupp, MGMT gene silencing
and benefit from temozolomide in glioblastoma, New Engl J
Med 352 (2005), 997–1003.
[18] J.G. Herman and S.B. Baylin, Gene silencing in cancer in
association with promoter hypermethylation, N Engl J Med
349 (2003), 2042–2054.
[19] Y. Iwadate, T. Sakaida, T. Hiwasa, Y. Nagai, H. Ishikura, M.
Takiguchi and A. Yamaura, Molecular classification and sur-
vival prediction in human gliomas based on proteome analysis,
Cancer Res 64 (2004), 2496–2501.
[20] K.A. Jaeckle, H.J. Eyre, J.J. Townsend, S. Schulman,
H.M. Knudson, M. Belanich, D.B. Yarosh, S.I. Bear-
man, D.J. Giroux and S.C. Schold, Correlation of tumor
O6 methylguanine-DNA methyltransferase levels with sur-
vival of malignant astrocytoma patients treated with bis-
chloroethylnitrosourea: a Southwest Oncology Group study,
J Clin Oncol 16 (1998), 3310–3315.
[21] R. Jaenisch and A. Bird, Epigenetic regulation of gene expres-
sion: how the genome integrates intrinsic and environmental
signals, Nat Genet 33 (2003), 245–254.
[22] M. Kanamori, H. Kon, T. Nobukuni, S. Nomura, K. Sugano, S.
Mashiyama, T. Kumabe, T. Yoshimoto, M. Meuth, T. Sekiya
and Y. Murakami, Microsatellite instability and the PTEN1
gene mutation in a subset of early onset gliomas carrying
germline mutation or promoter methylation of the hMLH1
gene, Oncogene 19 (2000), 1564–1571.
[23] P. Karran, Mechanisms of tolerance to DNA damaging thera-
peutic drugs, Carcinogenesis 22 (2001), 1931–1937.
[24] G. Kitange, B.L. Carlson, J. LaMont, M. Schroeder, J.N.
Sarkaria and C.D. James, Use of an orthotopic xenograft model
and corresponding xenograft cell cultures to evaluate MGMT
promoter hypermethylation and temozolomide response in
glioblastoma, Proc Amer Assoc Cancer Res 47 (2006), [Ab-
stract #5676].
[25] P. Kleihues, D.N. Louis, B.W. Scheithauer, L.B. Rorke, G.
Reifenberger, P.C. Burger and W.K. Cavenee, The WHO clas-
sification of tumors of the nervous system, J Neuropathol Exp
Neurol 61 (2002), 215–225; discussion 226–229.
[26] Y. Liang, M. Diehn, N. Watson, A.W. Bollen, K.D. Aldape,
M.K. Nicholas, K.R. Lamborn, M.S. Berger, D. Botstein, P.O.
Brown and M.A. Israel, Gene expression profiling reveals
molecularly and clinically distinct subtypes of glioblastoma
multiforme, Proc Natl Acad Sci USA 102 (2005), 5814–5819.
Epub 2005 Apr 12.
[27] R. Martinez, H.K. Schackert, J. Plaschke, G. Baretton, H.
Appelt and G. Schackert, Molecular mechanisms associated
with chromosomal and microsatellite instability in sporadic
glioblastoma multiforme, Oncology (2004), 395–403.
[28] P.S. Mischel, T.F. Cloughesy and S.F. Nelson, DNA-
microarray analysis of brain cancer: molecular classification
for therapy, Nat Rev Neurosci 5 (2004), 782–792.
[29] M. Mollemann, M. Wolter, J. Felsberg, V.P. Collins and G.
Reifenberger, Frequent promoter hypermethylation and low
expression of the MGMT gene in oligodendroglial tumors, Int
J Cancer 113 (2005), 379–385.
[30] A. Natsume, D. Ishii, T. Wakabayashi, T. Tsuno, H. Hatano,
M. Mizuno and J. Yoshida, IFN-beta down-regulates the ex-
pression of DNA repair gene MGMT and sensitizes resistant
glioma cells to temozolomide, Cancer Res 65 (2005), 7573–
7579.
[31] J.M. Nigro, A. Misra, L. Zhang, I. Smirnov, H. Colman, C.
Griffin, N. Ozburn, M. Chen, E. Pan, D. Koul, W.K. Yung, B.G.
Feuerstein and K.D. Aldape, Integrated array-comparative ge-
nomic hybridization and expression array profiles identify
clinically relevant molecular subtypes of glioblastoma, Can-
cer Res 65 (2005), 1678–1686.
[32] C.L. Nutt, D.R. Mani, R.A. Betensky, P. Tamayo, J.G. Cairn-
cross, C. Ladd, U. Pohl, C. Hartmann, M.E. McLaughlin, T.T.
Batchelor, P.M. Black, A. von Deimling, S.L. Pomeroy, T.R.
Golub and D.N. Louis, Gene expression-based classification
of malignant gliomas correlates better with survival than his-
tological classification, Cancer Res 63 (2003), 1602–1607.
[33] K. Ochs and B. Kaina, Apoptosis induced by DNA dam-
age O6-methylguanine is Bcl-2 and caspase-9/3 regulated and
Fas/caspase-8 independent, Cancer Res 60 (2000), 5815–
5824.
[34] H.S. Phillips, S. Kharbanda, R. Chen, W.F. Forrest, R.H. Sori-
ano, T.D. Wu, A. Misra, J.M. Nigro, H. Colman, L. Soroceanu,
P.M. Williams, Z. Modrusan, B.G. Feuerstein and K. Aldape,
Molecular subclasses of high-grade glioma predict prognosis,
delineate a pattern of disease progression, and resemble stages
in neurogenesis, Cancer Cell 9 (2006), 157–173.
[35] J.A. Quinn, A. Desjardins, J. Weingart, H. Brem, M.E. Dolan,
S.M. Delaney, J. Vredenburgh, J. Rich, A.H. Friedman, D.A.
Reardon, J.H. Sampson, A.E. Pegg, R.C. Moschel, R. Birch,
R.E. McLendon, J.M. Provenzale, S. Gururangan, J.E. Dancey,
J. Maxwell, S. Tourt-Uhlig, J.E. Herndon, 2nd, D.D. Bigner
and H.S. Friedman, Phase I trial of temozolomide plus O6-
benzylguanine for patients with recurrent or progressive ma-
lignant glioma, J Clin Oncol 23 (2005), 7178–7187.
[36] J.N. Rich, C. Hans, B. Jones, E.S. Iversen, R.E. McLen-
don, B.K. Rasheed, A. Dobra, H.K. Dressman, D.D. Bigner,
J.R. Nevins and M. West, Gene expression profiling and ge-
netic markers in glioblastoma survival, Cancer Res 65 (2005),
4051–4058.
[37] S.A. Schwartz, R.J. Weil, R.C. Thompson, Y. Shyr, J.H.
Moore, S.A. Toms, M.D. Johnson and R.M. Caprioli,
Proteomic-based prognosis of brain tumor patients using
direct-tissue matrix-assisted laser desorption ionization mass
spectrometry, Cancer Res 65 (2005), 7674–7681.
[38] L. Shen, Y. Kondo, G.L. Rosner, L. Xiao, N.S. Hernandez,
J. Vilaythong, P.S. Houlihan, R.S. Krouse, A.R. Prasad, J.G.
Einspahr, J. Buckmeier, D.S. Alberts, S.R. Hamilton and J.P.
Issa, MGMT promoter methylation and field defect in sporadic
colorectal cancer, J Natl Cancer Inst 97 (2005), 1330–1338.
[39] J.R. Silber, A. Blank, M.S. Bobola, S. Ghatan, D.D. Kolstoe
and M.S. Berger, O6-methylguanine-DNA methyltransferase-
deficient phenotype in human gliomas: frequency and time to
tumor progression after alkylating agent-based chemotherapy,
Clin Cancer Res 5 (1999), 807–814.
[40] L.A. Stewart, Chemotherapy in adult high-grade glioma: a
systematic review and meta-analysis of individual patient data
from 12 randomised trials, Lancet 359 (2002), 1011–1018.
[41] L. Stojic, R. Brun and J. Jiricny, Mismatch repair and DNA
damage signalling, DNA Repair (Amst) 3 (2004), 1091–1101.
[42] R. Stupp, P.-Y. Dietrich, S. Ostermann Kraljevic, A. Pica, I.
Maillard, P. Maeder, R. Meuli, R. Janzer, G. Pizzolato, R. Mi-
ralbell, F. Porchet, L. Regli, N. de Tribolet, R.O. Mirimanoff
and S. Leyvraz, Promising survival for patients with newly
diagnosed glioblastoma multiforme treated with concomitant
radiation plus temozolomide followed by adjuvant temozolo-
mide, J Clin Oncol 20 (2002), 1375–1382.
104 P. Hau et al. / MGMT methylation status: The advent of stratified therapy in glioblastoma?
[43] R. Stupp, M.E. Hegi, M.J. van den Bent, W.P. Mason,
M. Weller, R.O. Mirimanoff and J.G. Cairncross, Changing
paradigms–an update on the multidisciplinary management of
malignant glioma, Oncologist 11 (2006), 165–180.
[44] R. Stupp, W.P. Mason, M.J. van den Bent, M. Weller, B. Fisher,
M.J.B. Taphoorn, K. Belanger, A.A. Brandes, J.G. Cairncross,
C. Marosi, U. Bogdahn, J. Curschmann, R.C. Janzer, S. Lud-
win, T. Gorlia, A. Allgeier, D. Lacombe, E.A. Eisenhauer
and R.O. Mirimanoff, Radiotherapy plus concomitant and ad-
juvant temozolomide for glioblastoma, N Engl J Med 352
(2005), 987–996.
[45] S. Tanaka, I. Kobayashi, S. Utsuki, H. Oka, Y. Yasui and K. Fu-
jii, Down-regulation of O6-methylguanine-DNA methyltrans-
ferase gene expression in gliomas by platinum compounds,
Oncol Rep 14 (2005), 1275–1280.
[46] A.H. Ting, K.W. Jair, K.E. Schuebel and S.B. Baylin,
Differential requirement for DNA methyltransferase 1 in main-
taining human cancer cell gene promoter hypermethylation,
Cancer Res 66 (2006), 729–735.
